erlotinib has been researched along with tak 285 in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (tak 285) | Trials (tak 285) | Recent Studies (post-2010) (tak 285) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 26 | 2 | 25 |
| Protein | Taxonomy | erlotinib (IC50) | tak 285 (IC50) |
|---|---|---|---|
| Chain A, Epidermal growth factor receptor | Homo sapiens (human) | 0.023 | |
| Chain A, Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.023 | |
| Chain A, Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.017 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 1.6902 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0138 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 2.4 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 5.2 | |
| Hepatocyte growth factor receptor | Homo sapiens (human) | 4.2 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.023 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 4.7 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.1 | |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | 5.7 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1415 | |
| Aurora kinase B | Homo sapiens (human) | 1.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aertgeerts, K; Habuka, N; Hirokawa, A; Ishikawa, T; Iwamoto, K; Jennings, A; Miki, H; Ohta, Y; Sang, BC; Skene, R; Snell, G; Sogabe, S; Tanaka, T; Yano, J; Zou, H | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
2 other study(ies) available for erlotinib and tak 285
| Article | Year |
|---|---|
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
Topics: Allosteric Regulation; Antineoplastic Agents; Crystallography, X-Ray; Drug Design; Enzyme Activation; ErbB Receptors; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |